First-trimester exposure to ACE inhibitors is associated with congenital malformations
This article has no abstract so we have provided the first paragraph of the full text.
Women should not be given angiotensin-converting-enzyme (ACE) inhibitors during the second and third trimesters of pregnancy, as these drugs have been linked with an increased risk of fetopathy. Data on the use of ACE inhibitors in the first trimester are sparse, however, and researchers in the US have addressed this issue using data from 29,507 births recorded in the Tennessee Medicaid database.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
